Showing results (1-10 of 1,164) with videos related to
Sort By:
Pageof 117
Journal of Biopharmaceutical Statistics|July 16, 2019
The i3+3 design for phase I clinical trialsMeizi Liu, Sue-Jane Wang, Yuan JiJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trialsYuan Ji, Sue-Jane WangContemporary Clinical Trials|October 1, 2015
An integrated dose-finding tool for phase I trials in oncologyShengjie Yang, Sue-Jane Wang, Yuan JiContemporary Clinical Trials|May 21, 2021
Hi3 + 3: A model-assisted dose-finding design borrowing historical dataYunshan Duan, Sue-Jane Wang, Yuan JiContemporary Clinical Trials|May 2, 2017
A Bayesian interval dose-finding design addressingOckham's razor: mTPI-2Wentian Guo, Sue-Jane Wang, Shengjie Yang, et al.JCO Precision Oncology|August 24, 2022
Bayesian Sample Size Planning Tool for Phase I Dose-Finding TrialsXiaolei Lin, Jiaying Lyu, Shijie Yuan, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|January 9, 2009
Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development programSue-Jane WangPharmaceutical Statistics|October 25, 2007
Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSISue-Jane WangContemporary Clinical Trials|August 10, 2020
Recent advances in clinical trial design considerations in Thera"nostics"Sue-Jane WangJournal of Biopharmaceutical Statistics|November 9, 2010
Perspectives on the use of adaptive designs in clinical trials. Part I. Statistical considerations and issuesSue-Jane WangPageof 117